Hatteras Venture Partners could receive up to $20m from Malin for the $150m fund it is raising, having also secured GlaxoSmithKline and LabCorp as limited partners.

Pharmaceutical company Malin Corporation has committed $15m to the latest fund to be raised by US-based venture capital firm Hatteras Venture Partners (HVP), which reached a $91m first close yesterday.

HVP aims to raise $150m for its fifth fund, according to a regulatory filing. It invests across the healthcare technology spectrum, funding startups developing technology centred on medical devices, diagnostics, discovery science and clinical platforms, and healthcare IT.

Malin’s investment could potentially increase to $20m and was made as part…